Differentially expressed cellular genes following HBV: Potential targets of anti-HBV drugs?

Journal of Viral Hepatitis

Volumn 12, Issue 4, 2005, Pages 357-363

  Yang, J ^a   Bo, X C ^a   Yao, J ^b   Yang, N M ^b   Wang, Shengqi Q ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b Key Laboratory of HFRS   (China)

Author keywords

Gene expression; HBV; Host; Lamivudine; Microarray; Targets

Indexed keywords

ANTI HEPATITIS B VIRUS AGENT; ANTIVIRUS AGENT; LAMIVUDINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIVIRAL AGENTS; CELL LINE; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LAMIVUDINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 21844479587     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00611.x     Document Type: Article

References (34)

1. Liu J, Li YH, Xue CF et al. Targeted ribonuclease can inhibit replication of hepatitis B virus. World J Gastroenterol 2003; 9(2): 295-299.
2. Tang ZY. Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 2001; 7(4): 445-454.
3. Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335-1340.
4. Hoofnagle JH, Dibisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
5. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1(4): 232-241.
6. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64(1): 51-68.
7. Liu X, Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antivir Chem Chemother 2002; 13(3): 143-155.
8. Wing BA, Brown EP, Shenk T, et al. DNA microarrays: a powerful new tool for analysis of the virus-host interaction. DDT 2001; 6(15,suppl.): s67-s71.
9. Smith MW, Yue ZN, Korth MJ, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 2003; 38(6): 1458-1467.
10. Wieland SF, Vega RG, Muller R et al. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003; 77(2): 1227-1236.
11. Doong SL, Tsai CH, Schinazi RF et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499.
12. Li Wu-ju, Huang Jian, Fan Ming, Wang Sheng-qi et al. MProbe: computer aimed probe design for oligonucleotide microarray. Bioinformatics 2002; 1(3): 103-105.
13. Chen ZB, Yang J, Wang SQ et al. The preparation of positive comtrol in cDNA microarray and its application in sensitivity analysis. Lett Biotechnol 2002; 13(2): 103-107.
14. Chen ZB, Yang J, Wang SQ et al. Combining suppression subtractive hybridization (SSH) and cDNA microarray for rapid identification of differentially expressed genes from influenza virus infected host cells. Bing du xue bao 2003; 19(1): 21-26.
15. Geiss GK, Bumgarner RE, An MC et al. Large-scale monitor of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology 2000; 266: 268-316.
16. Park SG, Jung G. Human hepatitis B virus polymerase interacts with the molecular chaperonin Hsp60. J Virol 2001; 75(15): 6962-6968.
17. De Meyer S, Gong ZJ, Suwandhi W, van Pelt J, Soumillion A, Yap SH. Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes. J Viral Hepat 1997; 4: 145-153.
18. Ginam Cho, Sung-Gyoo Park, Guhung Jung. Localization of HSP90 binding sites in the human hepatitis B virus polymerase. Biochem Biophys Res Comm 2000; 269(1): 191-196.
19. Ori A, Zauberman A, Doitch G, Paran N, Oren M, Shaul Y. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J 1998; 17: 544-553.
20. Milena Panteva, Hasan Korkaya, Shahid Jameel. Hepatitis viruses and the MAPK pathway: is this a survival strategy? Virus Res 2003; 92: 131-140.
21. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64(1): 51-68.
22. Kang-Park S, Lee JH, Shin JH, Lee YI. Activation of the IGF-II gene by HBV-X protein requires PKC and p44/p42map kinase signalings. Biochem Biophys Res Commun 2001; 283: 303-307.
23. Ogden SK, Lee KC, Barton MC. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of a-fetoprotein gene expression. J Biol Chem 2000; 275: 27806-27814.
24. Gervain J, Papp I, Csondes M. Determination of the lamivudine-resistant mutants of hepatitis B virus. Orv Hetil 2003; 144(25): 1251-1256.
25. Otsuka M, Aizaki H, Kato N et al. Differential cellular gene expression induced by hepatitis B and C viruses. Biochem Biophys Res Comm 2003; 300(2): 443-447.
26. Treichel U, Buschenfelde KHMZ, Stockert RJ et al. The asialoglycoprotein recertor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic crriers. J Gen Virol, 1994; v75: 3021-3029.
27. Treichel U, Buschenfelde KHMZ, Gerken G et al. Receptor-mediated entry of hepatitis B virus particles into liver cells. Arch Virol 1997; 142: 493-498.
28. Lu YY, Cheng J, Liang YD et al. Cloning of a gene coding for novel mutant asialoglycoprotein receptor 2 binding to hepatitis B virus X protein in hepatocytes. Shijie Huaren Xiaohua Zazhi 2003; 11(1): 920-924.
29. Chen RF, Chen GJ, Huang XW. Effect of lamivudine on indirect impedance hepatic fibrosis. Chin J Lab Diagn 2002; 6(3): 138-139.
30. Budkowska A, Bedossa P, Groh F. Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain. J Virol 1995; 69(2): 840-848.
31. Lai CL, Chien RN, Laung NWY. A One-Year Trial of Lamivudine for Chronic Hepatitis B. N Engl J Med 1998; 339(2): 61-68.
32. Weisz A, Marx P, Sharf R et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 1992; 267(35): 25589-25596.
33. Sgarbanti M, Borsetti A, Moscufo N et al. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 2002; 195(10): 1359-1370.
34. Thornton AM, Buller FM, Devico AL et al. Inhibition of human immunodeficiency virus type 1 and caccinia virus infection by a dominant negative factor of the interferon regulatory factor family expressed in monocytic cells. Proc Natl Acad Sci USA, 1996; 93(1): 383-387.